Berman Capital Advisors’s UroGen Pharma URGN Stock Holding History

Berman Capital Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$7K	Buy	+468	New	+$7.42K	﹤0.01%	1341

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Berman Capital Advisors's URGN Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in UroGen Pharma (URGN) in Q3 2021: 468 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #1341 among its holdings.

93 funds tracked by Wall St. Rank hold URGN as of Q3 2021.

Berman Capital Advisors held 468 shares of UroGen Pharma worth $7K as of Q3 2021.
UroGen Pharma was a new Berman Capital Advisors position in Q3 2021.
UroGen Pharma made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1341 holding.
93 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.